10-Q Filing

KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC CIK: 1730430 Q2 2019

Filing Information

Form Type	10-Q
Accession Number	`0001558370-19-008069`
Period End Date	20190630
Filing Date	20190813
Fiscal Year	2019
Fiscal Period	Q2
XBRL Instance	knsa-20190630.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 52 Income Statement 58 Cash Flow Statement 52 Stockholders Equity 32

Balance Sheet 52 line items

Line Item	Tag	Value	Unit	Period
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$71.98M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$82.81M	USD	Point-in-time
Short-term investments	`ShortTermInvestments`	$204.64M	USD	Point-in-time
Short-term investments	`ShortTermInvestments`	$235.33M	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$9.01M	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$6.45M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$296.46M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$313.75M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$6.36M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$6.36M	USD	Point-in-time
Operating lease right-of-use assets	`OperatingLeaseRightOfUseAsset`	$2.50M	USD	Point-in-time
Operating lease right-of-use assets	`OperatingLeaseRightOfUseAsset`	$3.68M	USD	Point-in-time
Restricted cash	`RestrictedCashNoncurrent`	$210.00K	USD	Point-in-time
Restricted cash	`RestrictedCashNoncurrent`	$210.00K	USD	Point-in-time
Deferred offering costs	`DeferredCosts`	$433.00K	USD	Point-in-time
Deferred tax assets	`DeferredIncomeTaxAssetsNet`	$1.22M	USD	Point-in-time
Deferred tax assets	`DeferredIncomeTaxAssetsNet`	$2.61M	USD	Point-in-time
Total assets	`Assets`	$308.14M	USD	Point-in-time
Total assets	`Assets`	$321.96M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$9.34M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$10.92M	USD	Point-in-time
Accrued expenses	`AccruedLiabilitiesCurrent`	$16.42M	USD	Point-in-time
Accrued expenses	`AccruedLiabilitiesCurrent`	$19.18M	USD	Point-in-time
Accrued milestones	`AccruedMilestoneLiabilitiesCurrent`	$15.00M	USD	Point-in-time
Operating lease liabilities	`OperatingLeaseLiabilityCurrent`	$1.50M	USD	Point-in-time
Other current liabilities	`OtherLiabilitiesCurrent`	$165.00K	USD	Point-in-time
Other current liabilities	`OtherLiabilitiesCurrent`	$218.00K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$42.55M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$30.18M	USD	Point-in-time
Noncurrent operating lease liabilities	`OperatingLeaseLiabilityNoncurrent`	$1.82M	USD	Point-in-time
Other long-term liabilities	`OtherLiabilitiesNoncurrent`	$144.00K	USD	Point-in-time
Other long-term liabilities	`OtherLiabilitiesNoncurrent`	$943.00K	USD	Point-in-time
Total liabilities	`Liabilities`	$32.94M	USD	Point-in-time
Total liabilities	`Liabilities`	$42.70M	USD	Point-in-time
Commitments and contingencies (Note 12)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies (Note 12)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$473.48M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$572.32M	USD	Point-in-time
Accumulated other comprehensive income (loss)	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$101.00K	USD	Point-in-time
Accumulated other comprehensive income (loss)	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-4.00K	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-297.24M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-194.22M	USD	Point-in-time
Total shareholders equity	`StockholdersEquity`	$306.52M	USD	Point-in-time
Total shareholders equity	`StockholdersEquity`	$-89.71M	USD	Point-in-time
Total shareholders equity	`StockholdersEquity`	$-105.11M	USD	Point-in-time
Total shareholders equity	`StockholdersEquity`	$279.27M	USD	Point-in-time
Total shareholders equity	`StockholdersEquity`	$275.20M	USD	Point-in-time
Total shareholders equity	`StockholdersEquity`	$341.80M	USD	Point-in-time
Total liabilities and shareholders equity	`LiabilitiesAndStockholdersEquity`	$321.96M	USD	Point-in-time
Total liabilities and shareholders equity	`LiabilitiesAndStockholdersEquity`	$308.14M	USD	Point-in-time

Income Statement 58 line items

Line Item	Tag	Value	Unit	Period
Research and development expense	`ResearchAndDevelopmentExpense`	$17.20M	USD	1 Quarter
Research and development expense	`ResearchAndDevelopmentExpense`	$29.83M	USD	2 Qtrs
Research and development expense	`ResearchAndDevelopmentExpense`	$30.85M	USD	1 Quarter
Research and development expense	`ResearchAndDevelopmentExpense`	$90.10M	USD	2 Qtrs
General and administrative	`GeneralAndAdministrativeExpense`	$8.04M	USD	2 Qtrs
General and administrative	`GeneralAndAdministrativeExpense`	$16.84M	USD	2 Qtrs
General and administrative	`GeneralAndAdministrativeExpense`	$8.44M	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$4.33M	USD	1 Quarter
Total operating expenses	`OperatingExpenses`	$21.53M	USD	1 Quarter
Total operating expenses	`OperatingExpenses`	$39.29M	USD	1 Quarter
Total operating expenses	`OperatingExpenses`	$106.94M	USD	2 Qtrs
Total operating expenses	`OperatingExpenses`	$37.87M	USD	2 Qtrs
Loss from operations	`OperatingIncomeLoss`	$-21.53M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-37.87M	USD	2 Qtrs
Loss from operations	`OperatingIncomeLoss`	$-106.94M	USD	2 Qtrs
Loss from operations	`OperatingIncomeLoss`	$-39.29M	USD	1 Quarter
Interest income	`InvestmentIncomeInterest`	$1.07M	USD	1 Quarter
Interest income	`InvestmentIncomeInterest`	$1.37M	USD	2 Qtrs
Interest income	`InvestmentIncomeInterest`	$1.72M	USD	1 Quarter
Interest income	`InvestmentIncomeInterest`	$3.53M	USD	2 Qtrs
Loss before benefit for income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-20.46M	USD	1 Quarter
Loss before benefit for income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-103.40M	USD	2 Qtrs
Loss before benefit for income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-37.56M	USD	1 Quarter
Loss before benefit for income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-36.50M	USD	2 Qtrs
Benefit for income taxes	`IncomeTaxExpenseBenefit`	$-374.00K	USD	1 Quarter
Benefit for income taxes	`IncomeTaxExpenseBenefit`	$-391.00K	USD	2 Qtrs
Benefit for income taxes	`IncomeTaxExpenseBenefit`	$-202.00K	USD	1 Quarter
Benefit for income taxes	`IncomeTaxExpenseBenefit`	$-255.00K	USD	2 Qtrs
Net loss	`NetIncomeLoss`	$-20.26M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-65.82M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-103.01M	USD	2 Qtrs
Net loss	`NetIncomeLoss`	$-37.19M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-36.24M	USD	2 Qtrs
Net loss	`NetIncomeLoss`	$-15.98M	USD	1 Quarter
Net loss per share attributable to common shareholders - basic and diluted	`EarningsPerShareBasicAndDiluted`	$-1.11	USD	1 Quarter
Net loss per share attributable to common shareholders - basic and diluted	`EarningsPerShareBasicAndDiluted`	$-3.45	USD	2 Qtrs
Net loss per share attributable to common shareholders - basic and diluted	`EarningsPerShareBasicAndDiluted`	$-0.68	USD	1 Quarter
Net loss per share attributable to common shareholders - basic and diluted	`EarningsPerShareBasicAndDiluted`	$-1.94	USD	2 Qtrs
Weighted average common shares outstanding - basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	54.48M	shares	1 Quarter
Weighted average common shares outstanding - basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	18.33M	shares	1 Quarter
Weighted average common shares outstanding - basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	53.23M	shares	2 Qtrs
Weighted average common shares outstanding - basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	10.49M	shares	2 Qtrs
Net loss	`NetIncomeLoss`	$-65.82M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-20.26M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-103.01M	USD	2 Qtrs
Net loss	`NetIncomeLoss`	$-15.98M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-37.19M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-36.24M	USD	2 Qtrs
Unrealized gain on short-term investments	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$93.00K	USD	1 Quarter
Unrealized gain on short-term investments	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$105.00K	USD	2 Qtrs
Unrealized gain on short-term investments	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$12.00K	USD	1 Quarter
Unrealized gain on short-term investments	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$7.00K	USD	1 Quarter
Total other comprehensive loss	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent`	$105.00K	USD	2 Qtrs
Total other comprehensive loss	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent`	$93.00K	USD	1 Quarter
Total comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-37.10M	USD	1 Quarter
Total comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-20.26M	USD	1 Quarter
Total comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-102.91M	USD	2 Qtrs
Total comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-36.24M	USD	2 Qtrs

Cash Flow Statement 52 line items

Line Item	Tag	Value	Unit	Period
Net loss	`ProfitLoss`	$-36.24M	USD	2 Qtrs
Net loss	`ProfitLoss`	$-103.01M	USD	2 Qtrs
Depreciation expense	`Depreciation`	$20.00K	USD	2 Qtrs
Depreciation expense	`Depreciation`	$508.00K	USD	1 Quarter
Depreciation expense	`Depreciation`	$979.00K	USD	2 Qtrs
Depreciation expense	`Depreciation`	$12.00K	USD	1 Quarter
Share-based compensation expense	`ShareBasedCompensation`	$6.36M	USD	2 Qtrs
Share-based compensation expense	`ShareBasedCompensation`	$1.62M	USD	2 Qtrs
Class A common shares issued or to be issued as consideration for Primatope, including milestone payments	`IssuanceOfStockForAcquisition`	$8.80M	USD	2 Qtrs
Loss on disposal of property and equipment	`GainLossOnSaleOfPropertyPlantEquipment`	$-66.00K	USD	2 Qtrs
Non-cash rent expense	`NonCashRentExpense`	$208.00K	USD	2 Qtrs
Accretion of discounts on short-term investments	`AccretionAmortizationOfDiscountsAndPremiumsInvestments`	$2.06M	USD	2 Qtrs
Deferred income taxes	`DeferredIncomeTaxExpenseBenefit`	$-463.00K	USD	2 Qtrs
Deferred income taxes	`DeferredIncomeTaxExpenseBenefit`	$-1.39M	USD	2 Qtrs
Prepaid expenses, right-of-use assets and other assets	`IncreaseDecreaseInPrepaidExpenseRightOfUseAssetsAndOtherAssets`	$1.01M	USD	2 Qtrs
Prepaid expenses, right-of-use assets and other assets	`IncreaseDecreaseInPrepaidExpenseRightOfUseAssetsAndOtherAssets`	$2.96M	USD	2 Qtrs
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$-1.66M	USD	2 Qtrs
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$-747.00K	USD	2 Qtrs
Accrued expenses and other liabilities	`IncreaseDecreaseInAccruedLiabilities`	$5.62M	USD	2 Qtrs
Accrued expenses and other liabilities	`IncreaseDecreaseInAccruedLiabilities`	$2.72M	USD	2 Qtrs
Accrued milestones	`IncreaseDecreaseInAccruedMilestone`	$-15.00M	USD	2 Qtrs
Operating lease liabilities	`IncreaseDecreaseInOperatingLeaseLiabilities`	$-602.00K	USD	2 Qtrs
Other long-term liabilities	`IncreaseDecreaseInOtherNoncurrentLiabilities`	$943.00K	USD	2 Qtrs
Net cash provided by (used in) operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-32.89M	USD	2 Qtrs
Net cash provided by (used in) operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-104.93M	USD	2 Qtrs
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$767.00K	USD	2 Qtrs
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$311.00K	USD	2 Qtrs
Purchases of short-term investments	`PaymentsToAcquireShortTermInvestments`	$73.68M	USD	2 Qtrs
Purchases of short-term investments	`PaymentsToAcquireShortTermInvestments`	$273.49M	USD	2 Qtrs
Proceeds from the maturities of short-term investments	`ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments`	$306.34M	USD	2 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$32.09M	USD	2 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-73.99M	USD	2 Qtrs
Payments of offering costs	`PaymentsOfStockIssuanceCosts`	$2.83M	USD	2 Qtrs
Payments of offering costs	`PaymentsOfStockIssuanceCosts`	$118.00K	USD	2 Qtrs
Proceeds from exercise of options and employee share purchase plan	`ProceedsFromStockOptionsExercised`	$17.00K	USD	2 Qtrs
Proceeds from exercise of options and employee share purchase plan	`ProceedsFromStockOptionsExercised`	$693.00K	USD	2 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$347.21M	USD	2 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$83.68M	USD	2 Qtrs
Net increase in cash and cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect`	$240.33M	USD	2 Qtrs
Net increase in cash and cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect`	$10.83M	USD	2 Qtrs
Cash and cash equivalents and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$45.66M	USD	Point-in-time
Cash and cash equivalents and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$72.19M	USD	Point-in-time
Cash and cash equivalents and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$83.02M	USD	Point-in-time
Cash and cash equivalents and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$285.99M	USD	Point-in-time
Cash and cash equivalents and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$45.66M	USD	Point-in-time
Cash and cash equivalents and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$72.19M	USD	Point-in-time
Cash and cash equivalents and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$83.02M	USD	Point-in-time
Cash and cash equivalents and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$285.99M	USD	Point-in-time
Cash paid for income taxes	`IncomeTaxesPaid`	$1.03M	USD	2 Qtrs
Cash paid for income taxes	`IncomeTaxesPaid`	$148.00K	USD	2 Qtrs
Deferred offering costs included in accrued expenses and accounts payable	`DeferredOfferingCostsIncludedInAccruedExpensesAndAccountsPayable`	$856.00K	USD	2 Qtrs
Property and equipment included in accrued expenses and accounts payable	`CapitalExpendituresIncurredButNotYetPaid`	$253.00K	USD	2 Qtrs

Stockholders Equity 32 line items

Line Item	Tag	Value	Unit	Period
Balance at the beginning of the period	`StockholdersEquity`	$306.52M	USD	Point-in-time
Balance at the beginning of the period	`StockholdersEquity`	$-89.71M	USD	Point-in-time
Balance at the beginning of the period	`StockholdersEquity`	$-105.11M	USD	Point-in-time
Balance at the beginning of the period	`StockholdersEquity`	$279.27M	USD	Point-in-time
Balance at the beginning of the period	`StockholdersEquity`	$275.20M	USD	Point-in-time
Balance at the beginning of the period	`StockholdersEquity`	$341.80M	USD	Point-in-time
Conversion of convertible preferred shares into common shares	`StockIssuedDuringPeriodValueConversionOfConvertibleSecurities`	$310.59M	USD	1 Quarter
Common shares issued or to be issued in connection with the acquisition of all issued and outstanding equity securities of Primatope Therapeutics, Inc.	`StockIssuedDuringPeriodValueAcquisitions`	$7.00M	USD	1 Quarter
Common shares issued or to be issued in connection with a milestone payment due to Primatope Therapeutics, Inc.	`StockIssuedDuringPeriodValueMilestonePayments`	$1.80M	USD	1 Quarter
Exercise of options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$17.00K	USD	1 Quarter
Exercise of options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$512.00K	USD	1 Quarter
Exercise of options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$181.00K	USD	1 Quarter
Share-based compensation expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$1.06M	USD	1 Quarter
Share-based compensation expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$558.00K	USD	1 Quarter
Share-based compensation expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$3.46M	USD	1 Quarter
Share-based compensation expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$2.89M	USD	1 Quarter
Unrealized gain on short-term investments	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$93.00K	USD	1 Quarter
Unrealized gain on short-term investments	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$105.00K	USD	2 Qtrs
Unrealized gain on short-term investments	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$12.00K	USD	1 Quarter
Unrealized gain on short-term investments	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$7.00K	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-65.82M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-20.26M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-103.01M	USD	2 Qtrs
Net loss	`NetIncomeLoss`	$-15.98M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-37.19M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-36.24M	USD	2 Qtrs
Balance at the end of the period	`StockholdersEquity`	$275.20M	USD	Point-in-time
Balance at the end of the period	`StockholdersEquity`	$306.52M	USD	Point-in-time
Balance at the end of the period	`StockholdersEquity`	$-89.71M	USD	Point-in-time
Balance at the end of the period	`StockholdersEquity`	$-105.11M	USD	Point-in-time
Balance at the end of the period	`StockholdersEquity`	$279.27M	USD	Point-in-time
Balance at the end of the period	`StockholdersEquity`	$341.80M	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.